Related Companies

• Avacta Group

Pharmaceuticals & Biotechnology

News for Spread Betters

Previous

Next

There's a new Investor Edition of CMC Markets' spread betting platform... and it's exclusive to DigitalLook.com users...

Get full details about Marketmaker:Investor Edition here.

News for Spread Betters

Previous

Next

There's a new Investor Edition of CMC Markets' spread betting platform... and it's exclusive to DigitalLook.com users...

Get full details about Marketmaker:Investor Edition here.

Unsecured Loans

Previous

Next

Lighten the load of all those repayments with a low rate unsecured loan. This month's selected offers:

1. Barclays Loans
2. Halifax Loans

AMEX Platinum

Previous

Next

Money back on your spendings? With American Express Platinum MoneyBack card, you can get

• 5% Money Back* during your first 3 months, then
• standard Money Back rate up to 1.5% with
• typical APR 18.9% variable

Why look further? Apply now!

Digital Look's Best Picks

Previous

Next

Your money can work for you! Get it going with one of this month’s high interest current accounts:

1. A&L Premier Direct
2. Coventry First Account
3. Co-operative Current Plus

Date: Thursday 21 Aug 2008

LONDON (ShareCast) - Detection and analysis technology company Avacta said products in its development portfolio remain on track for release within previously indicated timeframes.

Since the company’s update last month on development activities the company has achieved milestones on Optim, its flagship product, and on a prototype technology based around Raman spectroscopy.

Optim, an instrument which performs biophysical analysis on minute amounts of biological and biopharmaceutical samples, completed its alpha prototype stage and remains on track for launch later this year or early in 2009.

Customer feedback with the product’s intended target audience has been positive.

Development of a prototype technology aimed at improving the sensitivity of Raman spectroscopy has been completed.

Raman spectroscopy is a commonly used chemical identification and analysis technique, but commercialisation has hitherto been limited because of weak signals and interference from background noise.

Several parties have expressed interest in licensing Avacta’s Raman technology and discussions with these are ongoing.

Avacta’s contract services division continues to trade profitably and add to its range of customers.

Avacta expects full year results, due to be announced in October, will demonstrate a period of revenue growth, product development and industry collaboration.

• News Channel